Business
Launch of LeanBiome with global nutrition leader
Launch of LeanBiome with global nutrition leader.
About this update from Optibiotix Health Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 1039U\n OptiBiotix Health PLC\n 01 December 2021\n \n \n \n OptiBiotix Health plc\n (\"OptiBiotix\" or the \"Company\")\n \n \n \n Launch of \n \n \n LeanBiomeTM\n \n \n with global leader in beauty & nutrition brands\n \n \n \n \n \n \n OptiBiotix Health plc (AIM: OPTI), \n announces the launch of a new sports nutrition product range branded LeanBiomeTM\n alongside a new supply & licensing agreement with a leading global player in beauty & nutrition (\"the Partner\"). This agreement grants the Partner a license to manufacture and sell finished products containing LeanBiomeTM\n across Europe, \n Australia and Asia. \n \n \n \n \n \n OptiBiotix is a life sciences business developing patented science and human study-based compounds that modulate the microbiome to address metabolic syndrome and diabetes, systemic low-grade inflammation, obesity, cardiovascular disease, high cholesterol and supports healthy aging.\n \n \n \n \n \n The Partner is a British e-commerce company which specialises in taking beauty and nutrition brands direct to consumer (\"D2C\") through its proprietary e-commerce platform across the globe. The Partner's technology, brand building expertise, and global infrastructure allows it to reach millions of customers around the world. They own the largest D2C sports nutrition brand globally.\n \n \n \n \n \n LeanBiomeTM\n is a scientifically formulated sports nutrition ingredient which has been developed by OptiBiotix that supports athletes seeking to increase lean muscle mass to change their body composition. LeanBiomeTM contains a patented combination of fibres, prebiotics and minerals aimed specifically at supporting the microbiome diversity of athletes on a high protein diet. LeanBiomeTM adds unique differentiation to a new premium product line of the Partner and will get on-pack recognition. The new product line of the Partner is aimed at increasing lean muscle mass which is scheduled to be rolled out from January 2022 in Europe and Asia. If the product line is successful, it is expected to be introduced to the North American market in due course. The agreement is expected to generate approximately £1m in annualised and recurring turnover for the Company starting in 2022. First orders worth...